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The Journal of Immunology
The Aryl Hydrocarbon Receptor Modulates Acute and Late
Mast Cell Responses
Riccardo Sibilano,*,1 Barbara Frossi,* Marco Calvaruso,† Luca Danelli,*
Elena Betto,* Alessandra Dall’Agnese,* Claudio Tripodo,† Mario P. Colombo,‡
Carlo E. Pucillo,* and Giorgia Gri*
The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor whose activity is modulated by xenobiotics as well as
physiological ligands. These compounds may modulate inflammatory responses and contribute to the rising prevalence of allergic
diseases observed in industrialized countries. Mast cells (MCs), located within tissues at the boundary of the external environment,
represent a potential target of AhR ligands. In this study, we report that murine and humanMCs constitutively express AhR, and its
activation by the high-affinity ligand 6-formylindolo[3,2-b]carbazole (FICZ) determines a boost in degranulation. On the contrary,
repeated exposure to FICZ inhibits MC degranulation. Accordingly, histamine release, in an in vivo passive systemic anaphylactic
model, is exacerbated by a single dose and is attenuated by repetitive stimulation of AhR. FICZ-exposed MCs produce reactive
oxygen species and IL-6 in response to cAMP-dependent signals. Moreover, AhR-activated MCs produce IL-17, a critical player in
chronic inflammation and autoimmunity, suggesting a novel pathway forMC activation in the pathogenesis of these diseases. Indeed,
histological analysis of patients with chronic obstructive pulmonary disease revealed an enrichment in AhR/IL-6 and AhR/IL-17
double-positive MCs within bronchial lamina propria. Thus, tissue-resident MCs could translate external chemical challenges
through AhR by modulating allergic responses and contributing to the generation of inflammation-related diseases. The Journal
of Immunology, 2012, 189: 120–127.
T
he aryl hydrocarbon receptor (AhR) is a member of the
basic helix-loop-helix-Per-Arnt-Sim transcriptional factor
family known to respond to environmental toxins, such as
dioxin, dioxin-like compounds, and benzopyrene found in cigarette
smoke, as well as to endogenous compounds, including dietary
components, heme metabolites, indigoids, and tryptophan metab-
olites. The binding to its agonist allows AhR nuclear translocation
and regulation of a large number of target genes containing dioxin
responsive elements on their enhancer sequences (1). Recent data
demonstrate that AhR influences immune responses and is in-
volved in inflammatory diseases, such as experimental auto-
immune encephalomyelitis (2), inflammatory bowel disease (3),
and inflammatory response to cigarette smoke (4). Several groups
have shown that AhR activation contributes to IL-17–producing
T cell (Th17) differentiation (5), whereas others have reported that
it induces natural CD4+CD25+Foxp3+ regulatory T (Treg) cells and
IL-10–producing Tr1 cells (6). Thus, the role of AhR in driving
a pro- or an anti-inflammatory response is still debated. Depending
on AhR agonists and the model of pathology considered, AhR may
worsen or ameliorate the disease (7).
Innate immune cells, which are specifically located at the in-
terface between host and external environment and play important
roles in detoxification and protection from injury, may mediate the
immunological effects of AhR modulation in vivo. Among others,
mast cells (MCs) have been indicated as potent linkers between
innate and adaptive immunity because of their capacity to selec-
tively secrete cytokines and chemokines in response to a wide array
of stimuli and for their ability to regulate several physiological and
pathological immune responses (8). Additionally, we and others
have shown that MCs are precious allies of Treg cells in arranging
the tissue-restricted immune response, but their action may lead
both to tolerance or inflammation, depending on the molecular
milieu regulating Treg and effector T cells skewing into Th17 cells
(9). Therefore, AhR expression and its possible role in modulating
MC functions may have significant implications for the outcome
of inflammatory pathologies where effector T cell/Treg cell bal-
ance is compromised. Interestingly, a recent study shows that the
activation of AhR suppresses the development of Th2-mediated
food allergic response by inducing Treg cell skewing (10). How-
ever, these data do not exclude that AhR engagement could di-
rectly affect the function of allergy effector cells, namely MCs,
beyond T cells. Moreover, increasing evidence suggests alter-
ations in MC populations in patients with chronic obstructive
pulmonary disease (COPD), a chronic inflammatory disease
mostly associated with cigarette smoking in which innate and
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adaptive immune cells infiltrate and damage the bronchial mucosa
(11). Macrophages, neutrophils, and their proteolytic mediators are
involved in the extracellular matrix destruction, whereas CD8+
cytotoxic T cells and Th1 and Th17 cells produce proinflammatory
cytokines and promote accumulation of inflammatory cells in the
lungs. As COPD progresses to its severe stages, the MC population
in the lung changes its density, distribution, and phenotype (12),
possibly becoming relevant to the worsening of COPD. Because
the mechanisms by which lung MCs from COPD patients are
activated and because MC-specific contributions to the inflam-
matory milieu have not yet been characterized, we speculate that
the wide availability of AhR agonists in the lungs of these patients
could be responsible to promote MC activation.
In this study, we investigate the functional expression of AhR
in murine and human MCs discerning between early and late
responses. Early MC degranulation upon Ag-specific IgE cross-
linking in the presence of the AhR agonist 6-formylindolo[3,2-b]
carbazole (FICZ) and the possible mechanism of action are dis-
sected. To resemble the conceivable pathways of AhR ligand
exposure, MCs are treated with acute or repetitive schedules of
FICZ administration, revealing different behaviors.
Late IL-6 and IL-17 proinflammatory cytokine production upon
FICZ exposure are monitored from bone marrow-derived mast cells
(BMMCs) and human MC lines in vitro. Tissue resident MCs from
bronchial mucosa of COPD patients are analyzed for AhR, IL-6,
and IL-17 concomitant expression to verify MC potential to re-
spond to smoke-containing AhR ligands.
Materials and Methods
Mice, cell lines, and reagents
C57BL/6 mice were purchased from The Jackson Laboratory and used in
accordance with the National Institutes of Health Guidelines and Use
Committee. AhR-deficient (AhR2/2) mice were provided by Dr. Frank
Gonzalez (National Cancer Institute, Bethesda, MD). Human MC line
HMC-1 was cultured in RPMI 1640 medium supplemented with 10% FCS,
1.2 mM monothioglycerol, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 2 mM glutamine. Human LAD2 MC cell line was provided by Dr.
Arnold Kirshenbaum (National Institutes of Health) and grown in serum-
free StemPro-34 medium (Invitrogen, Carlsbad, CA) in the presence of
100 ng/ml human stem cell factor (PeproTech, London, U.K.). Human
liver carcinoma cell line HepG2 was cultured in RPMI 1640 medium
supplemented with 10% FBS.
DNP-specific IgE was produced as described (13). DNP human serum
albumin (DNP36-HSA, Ag) and N-acetyl-L-cysteine (NAC) were purchased
from Sigma-Aldrich (St. Louis, MO). The 6-formylindolo[3,2-b]carbazole
(FICZ) was purchased from Enzo Life Sciences (Farmingdale, NY). Protein
kinase A (PKA) inhibitor adenosine 39,59-cyclic monophosphorothioate,
Rp-isomer, triethylammonium salt (Rp-cAMP), and proteasome inhibitor
MG-132 were from Calbiochem (Merck, Darmstadt, Germany).
BMMC differentiation and activation
C57BL/6 murine BMMCs were obtained from in vitro differentiation of
bone marrow precursors as reported in Gri et al.(14). BMMCs (23 106/ml)
sensitized for 3 h with 1 mg/ml DNP-specific IgE were challenged in
Tyrode’s buffer with 50 ng/ml Ag.
Real-time PCR
RNAwas isolated using TRIzol reagent (Life Technologies, Carlsbad, CA)
according to the manufacturer’s instructions. RNA (1 mg) was reverse-
transcribed using an iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA). Murine ahr (forward, 59-ATGGCTTTGTGCTGGGTTGTCACAG-
39; reverse, 59-ACTCCTTGTGCAGAGTCTGGGTTT-39) and murine
g3pdh (forward, 59-TCAACAGCAACTCCCACTCTTCCA-39; reverse,
59-ACCCTGTTGCTGTAGCCGTATTCA-39) were synthesized and puri-
fied by MWG (Ebersberg, Germany). Real-time PCR was conducted using
iQ SYBR Green Supermix (Bio-Rad), according to manufacturer’s
instructions in CFX96 real-time system and analyzing data with CFX
Manager software (Bio-Rad). The fluorescent signals were collected dur-
ing extension phase, Ct values of the sample were calculated, and the
transcript levels were analyzed by the 22ΔΔCt method.
In vitro T cell differentiation
T cells were purified from spleen with a T cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cells (0.4 3 106) were placed on plate-
bound anti-CD3 (2 mg/ml) and anti-CD28 (2.5 mg/ml) in 1 ml final volume
RPMI 1640/5% FBS for 3 d. Th17 cells were obtained culturing anti-CD3/
anti-CD28–activated T cells with IL-6 (50 ng/ml), TGF-b (1 ng/ml), anti–
IL-4 (10 mg/ml), anti–IFN-g (10 mg/ml), and FICZ (300 nM) for 3 d.
Cell lysis and Abs
IgE-sensitized BMMCs (5 3 106) were treated with 50 ng/ml Ag in RPMI
1640 medium for 8, 16, and 24 h, washed, and lysed. For some conditions,
300 nM FICZ was added to culture medium in the presence or absence of
Ag. To inhibit AhR degradation, 7.5 mM MG-132 proteasome inhibitor
was added to BMMCs together with FICZ for 4 h. BMMC lysates were
prepared as in Sibilano et al. (15). Murine AhR, human AhR, and actin-
detecting Ab were purchased from Enzo Life Sciences, Abcam (Cam-
bridge, MA), and Sigma-Aldrich, respectively. Samples from 5 3 106
HepG2, LAD2, and HMC-1 cells were prepared as above. Percentage of
protein expression was obtained from densitometric analysis of band in-
tensity of AhR protein normalized to total actin.
Quantification of intracellular reactive oxygen species
Intracellular reactive oxygen species (ROS) were detected by incubating
2 3 105 BMMCs with 5 mM 5-(and-6)-chloromethyl-29,79-dichlorodihy-
drofluorescein diacetate acetyl ester (CM-H2DCFDA; Sigma-Aldrich) 15
min before addition of 300 nM FICZ or 5 mM H2O2 as a positive control
(Sigma-Aldrich). Thirty minutes later, cells were washed and relative
fluorescence intensities were quantified by flow cytometric analysis (FL-1
channel). In some experiments, before CM-H2DCFDA staining, BMMCs
were either treated for 30 min with 1 mM Rp-cAMP or 10 mM NAC or
with 300 nM FICZ for 16 and 3 h (repetitive treatment).
b-Hexosaminidase assay and cAMP quantification
IgE-presensitized BMMCs (5 3 105) in 250 ml Tyrode’s buffer were
challenged with 50 ng/ml Ag for 2.5, 5, 7.5, 10, and 30 min and the extent
of degranulation was measured by percentage of b-hexosaminidase re-
leased. In some experiments, 300 nM FICZ was added at the same time as
Ag. For repetitive treatment, FICZ was added to IgE-sensitized BMMCs
for 16 h, and then cells were washed and fresh FICZ was added to cell
culture for another 3 h before Ag. For cAMP quantification, 2 3 106 IgE-
presensitized BMMCs were treated as above for 2, 5, 10, and 30 min and
lysed in 200 ml 0.1 M HCl/0.1% Triton X-100. cAMP levels were mea-
sured with a Correlate-EIA direct cAMP enzyme immunoassay (Assay
Designs, Enzo Live Sciences).
Systemic anaphylaxis
C57BL/6 mice were sensitized with 3 mg mouse Ag-specific IgE by i.v.
injection 24 h before Ag challenge. For single dose treatment with FICZ,
mice received 100 mg/kg body weight FICZ in 200 ml PBS in the presence
or absence of 0.3 mg Ag. For repetitive treatment, mice were injected with
100 mg/kg body weight/200 ml FICZ 16 and 3 h before Ag. Then, 2.5 min
upon Ag challenge, mice were euthanized and blood was collected by
cardiac puncture for histamine ELISA quantification (Immunotech, Praha,
Czech Republic).
Cytokine quantification
IgE-sensitized BMMCs (2 3 106/ml) or human MC lines HMC-1 and
LAD2 were used for each condition. After 24 or 72 h with 300 nM FICZ,
50 ng/ml Ag, or Ag/FICZ stimulation, supernatants were collected and
tested for IL-6 or IL-17 production (murine IL-6 and IL-17 ELISA from
eBioscience, San Diego, CA; human IL-6 from Thermo Scientific, Wal-
tham, MA; human IL-17 from Ray Biotech, Norcross, GA). For IL-17
production, where indicated, a 4-h extra stimulus consisting of 50 ng/ml
PMA and 500 ng/ml ionomycin (both from Sigma-Aldrich) was given to
BMMCs prior supernatant collection. IL-2 and INF-g (CBA assay; Becton
Dickinson, San Jose, CA), IL-5 and IL-13 (ELISA; PeproTech), and IL-4,
IL-10, and IL-22 (ELISA; eBioscience) were measured in the supernatants
of 72 h-stimulated cells. Supernatants for TNF-a were tested 12 h after
stimulation (ELISA; eBioscience).
Selection of human samples
For in situ analyses, bioptic specimens of lung parenchyma from patients
with severe COPD (n = 4) and control specimens (n = 4 samples of normal
lung parenchyma) were collected from the archives of the Human Pa-
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thology Section, Department of Health Science, University of Palermo,
Italy. All the procedures followed were in accordance with the Helsinki
Declaration.
Histopathology and immunofluorescence
Histopathological analysis was performed on H&E and toluidine blue-
stained sections cut from formalin-fixed, paraffin-embedded specimens.
For in situ single-marker immunohistochemical analysis on lung tissue,
sections were treated using a microwave epitope retrieval technique with
10 mmol citrate buffer (pH 9.0) at high temperature for 20 min and were
incubated with anti-human tryptase and anti-human CD68 Abs (both from
Novocastra, Newcastle, U.K.) overnight at 4˚C. Staining was performed
with UltraVision Quanto detection system HRP polymer (Thermo Scien-
tific) and with 3,39-diaminobenzidine substrate-chromogen (Thermo Sci-
entific).
For in situ double-marker immunofluorescence on lung tissue, sections
underwent two sequential rounds of single-marker immunostaining as
previously reported (16). Anti-AhR (Abcam), anti–IL-6 (R&D Systems,
USA), anti–IL-17 (R&D Systems, Minneapolis, MN), anti-CD2 (Novo-
castra), and anti-tryptase (Santa Cruz Biotechnology, Santa Cruz, CA)
were adopted. After Fc blocking, Alexa Fluor-conjugated secondary Abs
(Invitrogen) were used. Slides were evaluated using a Leica DMI6000
microscope, and microphotographs were collected using a Leica
DFC350FX digital camera. Quantitative analysis of stained sections was
performed by counting the absolute number of fluorescent cells out of four
high-power microscopic fields (3400). Cells were counted by two expert
pathologists (M.C., C.T.) in a blinded fashion.
Statistical analysis
Results are expressed as means 6 SEM. Data were analyzed with a non-
paired Student t test (Prism; GraphPad Software, USA). Statistical sig-
nificance is indicated as follows: *p , 0.05, **p , 0.01, ***p , 0.001.
Results
BMMC degranulation is enhanced by transient AhR triggering
and inhibited by prolonged AhR stimulation
Quantitative PCR analysis showed that AhR was expressed in
BMMCs with levels comparable to Th17 cells (Fig. 1A). The
presence of AhR in BMMCs was confirmed by Western blot
analysis, which highlighted an ∼90 kDa protein band in wild-type
(WT), but not in AhR-deficient (AhR2/2), BMMC lysate (Fig.
1B). AhR triggering was performed using FICZ, a small synthetic
tryptophan-derivative compound, known to be a potent AhR ag-
onist (17). FICZ at 300 nM, which was the highest concentration
without effects on MC viability, was used throughout the in vitro
experiments (Supplemental Fig. 1A). Twenty-four hours after
FICZ exposure, AhR expression was reduced on the average of
646 5% in the absence and 596 5% in the presence of IgE-specific
Ag, respectively compared with AhR levels found in unstimulated
BMMCs (Fig. 1B). This finding is in accordance with previous
works showing that the exposure to AhR agonists causes AhR-ex-
pressing cells to downregulate the receptor through the ubiquitin/
proteasome degradation pathway (18, 19). To confirm that this
pathway mediates AhR downregulation also in MCs, cells were
treated with the proteasome inhibitor MG-132, together with FICZ
for 4 h. This treatment blocked ligand-dependent degradation of
AhR (Fig. 1C).
To study the role of AhR activation on MC responses to IgE
triggering, BMMCs were incubated with or without FICZ, in the
presence or absence of Ag. Degranulation was measured through
the release of MC granule-associated enzyme b-hexosaminidase at
different time points (Fig. 2A). FICZ treatment did not influence
degranulation in the absence of antigenic stimulation, whereas it
enhanced granule exocytosis at early stages of Ag response, for
example, 2.5, 5, and 7.5 min following Ag triggering (2.5 min: Ag,
20.25 6 1.57%, Ag/FICZ, 31.12 6 4.07%; 5 min: Ag, 25.42 6
0.27%, Ag/FICZ, 31.11 6 0.74%; 7.5 min, Ag: 31.95 6 0.19%,
Ag/FICZ, 35.25 6 0.50% b-hexosaminidase release; p = 0.03,
0.0004, and 0.002, respectively). This effect was AhR-specific,
since AhR-deficient BMMCs, whose FcεRI expression levels
were similar to WT BMMCs (Supplemental Fig. 1B), did not
display upregulation of b-hexosaminidase release upon FICZ
treatment (Fig. 2B). The consequence of in vivo AhR stimulation
on MC degranulation was then investigated in a model of passive
systemic anaphylaxis, known to be dependent on MC activity.
FICZ and Ag concurrent administration in mice caused a signifi-
cant and prompt increase in plasma histamine levels (measured
2.5 min after challenge), compared with Ag administration alone
(Fig. 2C; Ag, 931.7 6 82.4 ng/ml histamine; Ag/FICZ, 1389 6
128.2 ng/ml histamine; p = 0.008).
Because the presence of AhR ligands in the environment may
determine a repeated stimulation of AhR, the downstream
responses might differ from that activated by a single AhR trig-
gering. To address this issue, BMMCs were treated twice with
different schedules of 300 nM FICZ (Supplemental Fig. 1C). In all
conditions tested, degranulation was reduced, with the greatest
effect reached when FICZ was administered 16 and 3 h before Ag
triggering, in which degranulation was reduced in WT BMMCs
(Fig. 2D; Ag alone, 41.5 6 0.4% b-hexosaminidase; pre-exposure
to FICZ/Ag, 18.5 6 2.8% b-hexosaminidase; p = 0.015), but not
in AhR-deficient BMMCs (Fig. 2E). In this study, AhR protein
expression was decreased, but still detectable (Fig. 2F). Similarly,
in in vivo experiments of systemic anaphylaxis, repeated treatment
with FICZ caused a reduced release of histamine upon Ag chal-
lenge, as compared with Ag challenge alone (Fig. 2G; Ag, 33766
512.2 ng/ml histamine; pre-exposure to FICZ/Ag, 1490 6 180.5
ng/ml histamine; p = 0.008).
FIGURE 1. BMMCs express AhR, which is degraded via proteasome
upon FICZ ligation. (A) Quantitative PCR to compare levels of AhR
mRNA among resting or anti-CD3/anti-CD28–activated CD4+ T cells,
differentiated Th17 cells, and BMMCs. Results are expressed as fold in-
duction over resting CD4+ T cells. Means 6 SEM from three independent
experiments are shown. (B) Western blot analysis to verify AhR presence
in lysates from WT BMMCs, normalized to total actin. IgE-sensitized
BMMCs were left unstimulated (ns) or stimulated with FICZ, Ag, or Ag/
FICZ at indicated time points. Unstimulated AhR-deficient (AhR2/2)
BMMCs were used as control. Numbers indicate protein fold expression
relative to unstimulated BMMCs. (C) IgE-sensitized BMMCs were treated
with FICZ without or with 7.5 mM proteasome inhibitor MG-132 for 4 h.
Lysates were normalized to total actin and numbers indicate protein fold
expression relative to unstimulated BMMCs. One of three experiments is
shown.
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FICZ modulates cAMP, which is necessary for
Fc«RI-dependent degranulation and ROS production in
BMMCs
A shared intracellular mechanism regulating AhR-related functions
and FcεRI-dependent MC degranulation involves the cAMP sig-
naling, which is necessary for AhR translocation to the nucleus
and activation of reporter genes in many cell types (20), as well as
for appropriate MC granule exocytosis following FcεRI activation
(21). Thus, the effect of AhR triggering, either alone or in com-
bination with FcεRI crosslinking, on cAMP production was
evaluated. Single exposure to FICZ, concomitantly with Ag
challenge, significantly enhanced intracellular cAMP production
at 2 and 5 min, compared with untreated BMMCs, in WT (Fig.
3A; 2 min, 4.3 6 0.2-fold, p = 0.016; 5 min, 2.8 6 0.1-fold, p =
0.014), but not in AhR-deficient BMMCs (Fig. 3B). Interestingly,
in the absence of Ag, single exposure to FICZ was able to tran-
siently and rapidly enhance cAMP levels in WT BMMCs (Fig.
3C). On the contrary, 16 and 3 h FICZ pretreatment reduced in-
tracellular cAMP levels in response to the Ag in WT BMMCs but
not in AhR-deficient BMMCs (Fig. 3D), suggesting that repetitive
exposure to FICZ renders BMMCs anergic in cAMP production.
Because of the AhR-dependent proinflammatory scenario (5)
and the ability of MCs to produce ROS during inflammatory and
allergic responses (22), we analyzed whether AhR ligands lead to
ROS production. WT BMMCs, stained with the fluorescent dye
CM-H2DCFDA, consistently produced ROS in response to a sin-
gle dose of FICZ (Fig. 3E). This was not observed in AhR-
deficient BMMCs (Fig. 3F). To study the role of cAMP/PKA
signals on AhR-induced ROS production, BMMCs were pre-
treated with the PKA inhibitor Rp-cAMP. With these settings,
AhR-mediated ROS formation was inhibited (Fig. 3G). As for
cAMP (Fig. 3D), upon 16 and 3 h stimulation with FICZ, ROS
production was impaired (Fig. 3H), confirming that repetitive AhR
activation confers anergy to MCs.
FICZ stimulation sets the stage for the proinflammatory milieu
by inducing IL-6 and IL-17 production in murine and human
MCs
AhR is widely considered a key factor in driving the fate of Th17
differentiation (5) and in inducing IL-6 production itself (23),
whereas MCs represent a potent source of IL-6 and IL-17 in many
pathological conditions such as in the synovium in rheumatoid
arthritis, in osteoarthritis, and in psoriatic lesions (24–26). On
these bases, we investigated whether direct exposure to FICZ
could drive MCs to release IL-6 and IL-17. FICZ treatment in-
duced BMMC IL-6 production that was slightly increased by
concomitant Ag stimulation (Fig. 4A, open bars; FICZ, 155.9 6
15.6 pg/ml; Ag, 1204.7 6 53.2 pg/ml; Ag/FICZ, 1417.9 6 14.1
pg/ml), an effect absent in AhR-deficient BMMCs (Fig. 4A, filled
bars). AhR induces IL-6 production, in a human monocytic cell
line, via cAMP-dependent PKA activation (27). To test whether
AhR-induced cAMP correlates with IL-6 secretion, we used the
PKA inhibitor Rp-cAMP. Results showed that FICZ-induced IL-6
production was lowered in both unstimulated and Ag-stimulated
BMMCs in which the cAMP/PKA pathway was transiently
inhibited by Rp-cAMP (Fig. 4B; FICZ, 67.4 6 0.4 pg/ml; Rp-
cAMP/FICZ, 34.1 6 10.2 pg/ml; Ag/FICZ, 1070 6 9.2 pg/ml;
Ag/Rp-cAMP/FICZ, 761.7 6 10.8 pg/ml).
BMMC-derived IL-17 was evaluated as detailed for IL-6. After
72 h exposure to a single-dose of FICZ, BMMCs produced low
levels of IL-17 (Fig. 4C; FICZ, 70.16 0.4 pg/ml; Ag/FICZ, 86.06
6.4 pg/ml). To confirm FICZ-induced IL-17 production by
BMMCs, we provided an extra 4 h stimulus with PMA/ionomycin
known to enhance gene transcription. With this treatment, we were
able to detect a high basal level for IL-17 production, which
appeared further increased in the presence of Ag stimulation and
was enhanced by FICZ (Fig. 4D). Upon FICZ exposure, IL-17–
producing BMMCs were also detected through FACS analysis
(Supplemental Fig. 2A).
FIGURE 2. BMMC responsiveness to FICZ depends on treatment schedule. (A and B) Time course BMMC degranulation assay. (A) IgE-sensitized WT
BMMCs were stimulated with FICZ in the absence or presence of Ag and examined for b-hexosaminidase (b-hex) release at indicated time points. (B) IgE-
sensitized AhR-deficient (AhR2/2) BMMCs were stimulated and examined for b-hexosaminidase release as in (A). Numbers indicate means 6 SEM from
three independent experiments. (C) In vivo plasma histamine levels were measured 2.5 min upon challenge with PBS (n = 5), FICZ (n = 5), Ag (n = 9), and
Ag/FICZ (n = 9). (D and E) IgE-sensitized WT or AhR2/2 BMMCs were untreated or treated with FICZ for 16 and 3 h (16h+3h FICZ) before Ag addition.
b-hexosaminidase was quantified 30 min after Ag addition. Numbers indicate means 6 SEM from two independent experiments. (F) AhR protein ex-
pression after 16h+3h FICZ treatment. Lysates were normalized to total actin, and numbers indicate protein fold expression relative to unstimulated
BMMCs. One of three experiments is shown. (G) In vivo plasma histamine levels were measured as in (C). Mice were untreated or treated 16 and 3 h with
FICZ (16h+3h FICZ) and challenged with PBS (n = 3) or with Ag (n = 5). *p , 0.05, **p , 0.01, ***p , 0.001.
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The analysis of cytokine production was extended to Th1/Th2,
regulatory cytokines, and IL-22, which is coexpressed with IL-17
by Th17 cells (28). We found that, besides IL-17 and IL-6, FICZ
induced BMMC production of the proinflammatory IL-13 and the
regulatory IL-10 cytokines. Interestingly, the detection of the early
released mediator TNF-a, a classical cytokine that MCs can re-
lease upon Ag stimulation, was slightly enhanced in the copre-
sence of Ag and FICZ (Table I).
We subsequently investigated AhR expression and function in
human MCs. As shown in Fig. 4E, human MC lines HMC-1 and
LAD2 expressed AhR at different levels. Similar to murine
BMMCs, AhR stimulation by FICZ alone led to IL-6 (Fig. 4F,
filled bar; HMC-1, 68.9 6 29.7 pg/ml; LAD2, 79.1 6 4.5 pg/ml)
and IL-17 production (Fig. 4G, filled bar; HMC-1, not detected;
LAD2, 306.0 6 17.50 pg/ml). The latter was increased upon an
extra PMA/ionomycin stimulation (Fig. 4H, filled bar; HMC-1,
112.3 6 41.1 pg/ml; LAD2, 459.8 6 32.8 pg/ml).
Mast cells from COPD patients express AhR and are a relevant
in situ source of IL-6 and IL-17
The presence of AhR+ MCs, as well as the number of AhR+ cells
expressing IL-6 and IL-17, was assessed in lung specimens of
COPD patients by double immunofluorescence in situ. Overall,
a significantly increased number of MCs infiltrating the epithelial
layer and the lamina propria of the bronchial mucosa was
detected in samples from COPD patients as compared with
controls (Fig. 5A, 5C, toluidine blue and tryptase). Besides MCs,
other innate immune cells proved to be increased in the lung
parenchyma of patients with severe COPD (dendritic cell-SIGN-
positive myeloid dendritic cells and myeloperoxidase-positive
granulocytes; data not shown). However, differently from MCs,
macrophages mainly localized within the lamina propria of the
bronchus mucosa and in the interstitium between the alveoli, only
rarely extending inside the epithelium (Fig. 5A, 5C, CD68, tolu-
idine blue, and tryptase). These data suggest MCs as the innate
immune cells chiefly involved as sensors of epithelial damage in
the bronchus mucosa.
In COPD and control samples, AhR was comparably expressed
by epithelial cells (Fig. 5B, 5D), while characterizing a higher
number of tryptase-expressing MCs in COPD samples, compared
with controls. Moreover, COPD samples displayed a high amount
of AhR+/IL-6+ and AhR+/IL-17+ nonepithelial cells in the lamina
propria, which supported the contribution of AhR-expressing cells
in the molding of COPD inflammatory microenvironment. The
difference in the amount of AhR+/IL-6+ and AhR+/IL-17+ cells
observed between COPD and control samples was paralleled by
that of the amount of tryptase+/IL-6+ and tryptase+/IL-17+ MCs,
implicating MCs as the relevant source of IL-6 and IL-17 (Fig.
5D, 5E). Other tryptase-negative IL-17–producing cells were also
detected within the bronchial mucosal interface, which mainly
proved to be of T cell phenotype, as they expressed the CD2
marker (e.g., Th17 cells and/or TCRgd T cells).
Discussion
AhR functional expression has been reported in NK T cells, TCRgd
T cells, macrophages, and dendritic cells, all located at the in-
terface between innate and acquired immune system (25, 29, 30),
suggesting that environmental factors as well as metabolic prod-
ucts have a role in the development of local cells and immune
response. In this study, to our knowledge we show for the first time
that murine and human MCs constitutively express AhR, whose
activation by FICZ is able to influence both FcεRI-mediated early
degranulation response and FcεRI-independent IL-6 and IL-17
cytokine production.
FIGURE 3. FICZ regulates cAMP and ROS levels in BMMCs. (A) IgE-sensitized WT BMMCs were stimulated with Ag in the absence (Ag, open bars)
or presence of FICZ (Ag/FICZ, filled bars), and at the indicated time points cAMP intracellular levels were measured. (B) IgE-sensitized AhR2/2 BMMCs
were stimulated as in (A), and cAMP levels were measured. (C) In the absence of Ag stimulation, WT (white bars) or AhR-deficient (AhR2/2, gray bars)
BMMCs were treated with FICZ as in (A). (D) WT (white bars) and AhR-deficient BMMCs (AhR2/2, gray bars) were treated for 16 and 3 h with FICZ,
IgE-sensitized, and triggered with Ag for 5 min. (A–D) Numbers indicate cAMP fold induction over unstimulated BMMCs and are the means 6 SEM from
at least two independent experiments for each panel. (E) WT BMMCs were untreated (ns, gray histogram) or treated with FICZ (black line) or H2O2 (gray
line) and stained with ROS-specific dye CM-H2DCFDA. (F) AhR
2/2 BMMCs were treated and stained as in (E). (G) BMMCs were pretreated with PKA
antagonist Rp-cAMP (Rp-cAMP+FICZ, light gray line) or with NAC, used as control to lower ROS production (NAC+FICZ, dark gray line), stained, and
analyzed as in (E). (H) WT BMMCs were pretreated for 16 and 3 h with FICZ, stained, and analyzed as in (E). Results from one representative experiment
of three are shown. *p , 0.05, **p , 0.01, ***p , 0.001.
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BMMCs showed opposite responses to the Ag-dependent acti-
vation, according to the timing of exposure to FICZ. Single-dose
administration of FICZ together with the Ag enhanced IgE/Ag-
dependent MC activation, whereas repeated treatment rendered
MCs less responsive to antigenic stimulation both in vivo and
in vitro. In this regard, we might speculate that MC hyper-
responsiveness may be associated with abrupt and intense expo-
sure to AhR ligands commonly spread in industrialized countries
(e.g., dioxins, airborne pollutants, tryptophan-rich dietary com-
pounds), which may correlate with the onset of allergy and
allergy-related pathologies in young individuals who encounter
these compounds together with the allergen for the first time (31).
Strikingly, FICZ-dependent formation of ROS observed in our
experiments would also be in accordance and contribute to the
enhancement of the overall inflammatory acute response observed
in young allergic patients (32). Alternatively, repetitive exposure
to AhR-ligand pollutants could suppress MC degranulation and
attenuate the allergic response in favor of other types MC-
mediated responses (e.g., inflammatory responses) by directly
acting on AhR-mediated MC responsiveness (10). Consistently,
MC “desensitization” through a repetitive AhR activation may
suggest an association with approaching therapies to desensitize
patients (especially children) that develop severe IgE-mediated
anaphylactic responses against dietary compounds (33).
However, it remains to be fully established how repetitive ex-
posure to AhR agonists reduced IgE-induced MC degranulation
since levels of FcεRI molecules present on MC surface remained
unaffected during treatment with FICZ (data not shown). We
identified cytosolic cAMP, whose rapid and transient increase is
required for MC exocytosis of granule content following FcεRI
triggering (21), as a crucial mediator responsible for many effects
caused by agonist-activated AhR in MCs. Indeed, upon single
dose exposure to FICZ, we observed a transient boost in cAMP
production that enhanced Ag-dependent degranulation, whereas
after double exposure to FICZ, BMMCs were no longer able to
upregulate cAMP. This could be due to either direct adenylate
cyclase inhibition or enhancement of phosphodiesterase amount
and/or activity, which prevents AhR function.
Interestingly, the increase of cAMP content in the absence of
antigenic stimulation was not per se sufficient to induce degran-
ulation in MCs, but it was adequate for ROS generation. The role of
cAMP/PKA signals on ROS production is still debated, and op-
posite effects have been reported, depending on the compound used
to generate ROS and the cellular model used (34, 35). Our data
showed that FICZ-dependent increase of cAMP leads to ROS
production, as pretreatment with the transient PKA inhibitor Rp-
cAMP prevented FICZ-induced ROS formation both in murine
and human (data not shown) MCs.
The cAMP/PKA pathway induces IL-6 production in different
cell types (36, 37), and AhR activation is able to induce IL-6
production by de-repressing its promoter in tumor cell lines
(23). Accordingly, our findings revealed a close relationship be-
tween AhR stimulation, cAMP, and cAMP-dependent IL-6 pro-
duction. Indeed, the use of the transient PKA inhibitor Rp-cAMP
partially inhibited IL-6 production from FICZ-, Ag-, and Ag/
FICZ-stimulated BMMCs.
We have recently demonstrated the importance of MC-produced
IL-6 in mediating the inhibition of Treg cell suppression toward
Th17 differentiation (9) and, in this study, we show that a single
compound is able to skew MCs toward IL-6, IL-17, and IL-13
production by specifically activating AhR. The consequences of
this event could be now evaluated in diseases where MCs repre-
sent a potent source of proinflammatory cytokines and exposure to
AhR ligands is likely to occur (38). For instance, MCs alone or
together with other non-T immune cells are predominant IL-17+
cells in psoriatic lesions in human skin (25), in atherosclerotic
plaques (39), as well as in rheumatoid arthritis, osteoarthritis, and
spondyloarthritis synovium (24, 26, 40). Human MCs require the
Th17 lineage-defining transcription factor Rorc to produce IL-17
in response to different stimuli (24). In this study, we were not able
to detect Rorc in both unstimulated and FICZ-stimulated BMMCs
(Supplemental Fig. 2B). This result opens the perspective that, at
least for murine BMMCs, MCs are also eligible to use a proper
pathway to induce IL-17 transcription after FICZ exposure.
FIGURE 4. Murine and human MCs respond to FICZ by producing IL-6
and IL-17. (A) IL-6 presence was evaluated by ELISA in the supernatants
of WT (open bars) and AhR-deficient IgE-sensitized BMMCs (AhR2/2,
filled bars) untriggered (ns) or triggered with Ag in the absence or presence
FICZ for 24 h. (B) IL-6 presence was evaluated as in (A) in BMMCs not
treated (2 Rp-cAMP, open bars) or pretreated with PKA antagonist Rp-
cAMP (+ Rp-cAMP, filled bars). (C) IL-17 presence was measured in the
same conditions shown in (A), but supernatants were collected 72 h after
addition of stimuli. (D) IL-17 was measured as in (C) with an extra 4 h
stimulus with 50 ng/ml PMA and 500 ng/ml ionomycin (IONO) prior to
collection of supernatants. As positive control condition, BMMCs were
treated 72 h with 10 ng/ml PMA and 100 ng/ml ionomycin. For (A)–(D),
numbers indicate means 6 SEM of one representative of at least three
independent experiments. (E) Western blot analysis for AhR presence in
lysates from HepG2 human liver carcinoma cell line (positive control for
AhR) as well as human MC lines HMC-1 and LAD2 normalized to total
actin. Numbers indicate fold expression relatively to HepG2 cell line. (F
and G) IL-6 or IL-17 was evaluated by ELISA in the supernatants of LAD2
and HMC-1 cells, after 24 or 72 h stimulation with FICZ, respectively. (H)
IL-17 was measured as in (G) with an extra 4 h stimulus with 50 ng/ml
PMA and 500 ng/ml ionomycin (IONO) prior to collection of supernatants.
For panels (F)–(H), numbers indicate means 6 SEM from at least two
independent experiments. *p , 0.05, **p , 0.01.
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The main cause ascribed to the pathogenesis of COPD is the
exposure to cigarette smoke, which induces chronic inflammation
of the bronchial mucosa. Cigarette smoke contains several poly-
cyclic aromatic hydrocarbons and dioxins, known to function as
AhR ligands. IL-6 and IL-17 have been extensively detected in the
lungs of COPD patients (11). Although various therapeutical
approaches based on neutralizing Ab against proinflammatory
cytokines have been proposed to attenuate airway inflammation in
COPD (41, 42), the main source and the precise role of IL-6 and
IL-17 in this disease remain undefined. Conflicting results have
been also reported for the role of AhR in immunological
responses in the airways. Chiba et al. (43) have reported that AhR
activation in airway epithelial cells induces mucin secretion
through production of ROS, suggesting that antioxidant treatments
may be appropriate for patients with respiratory symptoms related
to dioxin exposure. On the contrary, Baglole et al. (44) have
shown that AhR activation by cigarette smoke extracts has a pro-
tective effect on airway inflammation by inducing the production
of the cytoprotective enzyme heme-oxygenase-1 by lung fibro-
blasts. The discrepancy between these results may be ascribed to
the model (human versus mouse cell lines), the mechanism
(structural damage versus inflammation), and AhR agonists
adopted. In this study, we show that AhR-positive MCs appear to
be one of the major sources of IL-6 and IL-17 in bronchial bi-
opsies from COPD patients. AhR positivity observed in human
MCs could be ascribed to the loss of mechanisms controlling AhR
expression, due to the potential prolonged exposure to AhR
ligands in COPD patients. These changes may represent, for ex-
ample, the loss of the AhR repressor and/or of proteasome func-
tionality in damaged tissues. Nevertheless, whether MCs are
central to or supportive for the pathogenesis of airway diseases
remains to be clarified. Airway MCs, exposed to environmental
Ags, may be activated via AhR and secrete proinflammatory
mediators, generating a process that culminates in chronic in-
flammation. In particular, MC-derived IL-17 may contribute to the
progress of inflammation, inducing epithelial cells to promote
neutrophil accumulation into the site of injury. Moreover, IL-6 and
IL-13 production are also associated with a pattern of airway
remodeling (45), contributing to the overall worsening of the
disease.
FIGURE 5. Presence of tryptase-,
AhR-, IL-6–, and IL-17–positive cells in
bronchial biopsies from COPD patients.
(A) H&E, toluidine blue (TB), tryptase
(Tryp), and CD68 staining of sections
from normal lung parenchyma (Ctrl).
(B) Double-marker immunofluorescence
analysis of AhR-, tryptase (Tryp)-, IL-
6–, IL-17–, and CD2-positive cells in
sections from normal lung parenchyma
(double stainings: AhR/Tryp: AhR
green, Tryp red; IL-6/Tryp, IL-6 green,
Tryp red; AhR/IL-6, AhR green, IL-6
red; IL-17/Tryp, IL-17 green, Tryp red;
AhR/IL-17, AhR green, IL-17 red; IL-
17/CD2: IL-17 green, CD2 red. Original
magnification,340). (C andD) Samples
from COPD patients were stained as in
(A) and (B), respectively. Arrows indi-
cate epithelial cells. (E) Counts of AhR/
Tryp (AhR+/Tryp+), IL-6/Tryp (IL-6+/
Tryp+), AhR/IL-6 (AhR+/IL-6+), IL-17/
Tryp (IL-17+/Tryp+), and AhR/IL-17
(AhR+/IL-17+) double-positive cells in
bronchial mucosa from four controls
(Ctrl) and four COPD samples. Cells
were detected and counted out of four
3400 high-power microscopic fields in
each case. Each symbol in graphs rep-
resents the average of double-positive
cells for each case, obtained as indi-
cated. *p , 0.05, ***p , 0.001.
Table I. Cytokine production of murine BMMCs in response to FICZ
ns FICZ Ag Ag/FICZ
IL-2, IL-4, IL-5, IL-22, IFN-g n.d. n.d. n.d. n.d.
IL-10 n.d. 170.0 6 45.0*** n.d. 150.0 6 25.0***
IL-13 n.d. 99.7 6 21.7*** 183.0 6 1.7 179.7 6 18.3
TNF-a 53.3 6 1.6 46.7 6 5.0 406.7 6 5.0 496.7 6 18.3*
IL-2, IL-4, IL-10, INF-g, IL-5, IL-13, and IL-22 were evaluated in the supernatants of IgE-sensitized BMMCs untriggered
(ns) or triggered with 50 ng/ml Ag (IgE/Ag) in the absence or presence of 300 nM FICZ for 72 h. Supernatants for TNF-a were
tested by ELISA 12 h after stimulation. Results are expressed as means 6 SEM from at least two independent experiments.
*p , 0.05, ***p , 0.001, compared with FICZ-untreated BMMCs.
n.d., Not detectable.
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Our study highlights a new and previously unappreciated role
of MCs through AhR activation in orchestrating inflammatory
responses. This could be extended to all those pathologies where
tissue/organ homeostasis is broken by an inflammatory MC-rich
infiltrate, likely accessible by AhR ligands derived from trypto-
phan metabolism, such as inflammatory bowel disease (3) and
eosinophilia-myalgia syndrome (46).
Our results lay the bases for forthcoming studies aimed at
a deeper understanding of the role of AhR in modulating MC
effector functions.
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